Incidence and Associated Risk Factors of ARC in the Trauma Critically Ill Older Than 50 Years Old

Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04766944
Collaborator
(none)
50
1
21
2.4

Study Details

Study Description

Brief Summary

This single-center prospective cohort study conducted at the adult trauma ICU of the Montreal General Hospital (MGH) affiliated with the McGill University Health Centre (MUHC) aims to determine the incidence and associated risk factors of augmented renal clearance (ARC) in critically ill trauma patients of 50 years old and above.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

Patients aged 50 years or older admitted to the ICU for traumatic brain injury (TBI) and/or polytrauma between January 2021 and October 2021 will be screened for study enrollment according to inclusion and exclusion criteria.

Research hypothesis :
  • Critically ill trauma patients aged 50 years or older admitted to the ICU present an augmented renal clearance;

  • A set of factors could predict, to a certain extent, the risk of developing ARC in critically ill trauma patients aged 50 years or older admitted to the ICU.

ARC will be assessed for every patient based on daily 8-hour urine collections started within the first 24 hours of ICU admission and daily serum creatinine concentrations. The first seven days will consist of daily urinary collection while only biweekly samples (days 10 and 14) will be collected for the second week. Since ARC is a time-sensitive event, the use of a deferred consent will allow for urine collection to begin as soon as possible after admission. All other data required for the study (demographic and other clinically relevant data) will be collected retrospectively once consent from surrogate or patient has been obtained. Data will be collected from study enrollment up until one of the following events :

  1. Day 14 of ICU stay ; 2) ICU discharge; 3) AKI onset; 4) institution of RRT; 5) Removal of urinary catheter; 6) Withdrawal of informed consent; 7) Death; whichever occurs first.

Data regarding demographic variables including age, gender, anthropometric measurements, admission diagnosis, nature of injuries, comorbidities, and length of stay (LOS) will be obtained through the patient's medical records as well as the clinical information system. Data concerning ventilation and 24-hour fluid balance will be obtained through nursing records. Information regarding drug therapy (e.g., vasopressor and antibiotic use) will be obtained through the MUHC software. The Injury Severity Score (ISS) score will be compiled from the local Trauma Registry, while the Sequential Organ Failure Assessment (SOFA) score will be calculated directly.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Incidence and Associated Risk Factors of Augmented Renal Clearance (ARC) in Critically Ill Trauma Patients of 50 Years Old and Above
Anticipated Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Critically ill trauma patients of 50 years old and above

Patients of 50 years old and above admitted to the Montreal General Hospital intensive care unit for trauma

Other: No intervention
No intervention

Outcome Measures

Primary Outcome Measures

  1. To determine the incidence of augmented renal clearance in critically ill trauma patients aged 50 years and older [Once a day, up to 14 days]

    The incidence of augmented renal clearance is dichotomic: presence or absence of augmented renal clearance defined as a creatinine clearance of ≥ 130 mL/min/m² measured by a daily 8 hour urine collection

Secondary Outcome Measures

  1. To determine demographic and clinical risk factors for ARC in critically ill trauma patients aged 50 years and older [Up to 14 days]

    Predictive variables of ARC to be included in the model include: age strata (50-59 years old, 60-69 years old, 70 years old and above; biological gender; type of trauma (TBI, polytrauma without TBI, combined polytrauma and TBI) and severity of trauma (Injury Severity Score (ISS score), Sequential Organ Failure Assessment (SOFA) score, severity of TBI (GSC score at admission). Other variables to be included in the model will depend on the number of cases observed with a minimum of 10 cases per variable.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Admission to the ICU for isolated traumatic brain injury (TBI), polytrauma without TBI or combined polytrauma and TBI

  • Expected ICU length of stay of more than 24 hours

  • Age of ≥ 50 years old at the time of admission

  • Serum creatinine ≤ 120 μmol/L at the time of admission

  • Presence of an indwelling urinary catheter

  • Consent is obtained from the patient or its surrogate decision-maker within 7 days of ICU admission

Exclusion Criteria:
  • History of renal replacement therapy (RRT) (intermittent dialysis or peritoneal dialysis), nephrectomy or renal transplant

  • Patient developing acute kidney injury (AKI)

  • ICU physician considered patient unsuitable for enrollment due to poor prognosis

  • Burn-related trauma

  • Patient is admitted > 48 hours post-traumatic event

Contacts and Locations

Locations

Site City State Country Postal Code
1 McGill University Health Centre Montréal Quebec Canada H4A3J1

Sponsors and Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marc M. Perreault, Full clinical professor, McGill University Health Centre/Research Institute of the McGill University Health Centre
ClinicalTrials.gov Identifier:
NCT04766944
Other Study ID Numbers:
  • 2020-6327
First Posted:
Feb 23, 2021
Last Update Posted:
Feb 23, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Marc M. Perreault, Full clinical professor, McGill University Health Centre/Research Institute of the McGill University Health Centre
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2021